Orgenesis

Orgenesis Inc., a publicly traded biotechnology company founded in 2008, is working to decentralize the production of cell and gene therapies (CGTs). The company's central strategy revolves around its Point of Care (POCare) Platform, which aims to make advanced, personalized treatments more affordable and accessible by moving manufacturing from centralized facilities to localized, in-hospital or near-hospital settings. This model is designed to reduce logistical complexities and costs associated with traditional CGT manufacturing, which often involves six-figure price tags per patient.

The company was founded by Sarah Ferber and is currently led by CEO Vered Caplan, who brings a background in engineering and has held entrepreneurial and leadership roles at various medical device and biotech companies for over two decades. Her experience in biomedical engineering and business development informs the company's strategy to create a more efficient and scalable pathway for advanced therapies. Under her guidance, Orgenesis has transitioned its business model, notably after the 2020 sale of its contract development and manufacturing organization (CDMO), Masthercell, which funded the pivot to the current POCare service platform. The company has since focused on building a global collaborative network of hospitals, research institutes, and industry partners.

Orgenesis's business model operates through two primary segments: Octomera and Therapies. The Octomera segment, formerly Morgenesis, manages the POCare services, including the deployment of Orgenesis Mobile Processing Units and Labs (OMPULs). These are prefabricated, GMP-compliant cleanroom facilities that can be made operational in 3-6 months, a significant reduction from the 18-24 months required for traditional facilities. The company's revenue streams are derived from POCare development and cell processing services, as well as the supply of materials to its hospital partners. The Therapies segment focuses on developing a pipeline of in-licensed and partnered therapeutic candidates spanning immuno-oncology, antiviral treatments, and regenerative medicine. Orgenesis partners with early-stage developers to bring these therapies into its network, aiming to generate long-term revenue through licensing agreements and royalties.

Keywords: cell and gene therapy, point-of-care manufacturing, decentralized production, autologous therapies, POCare platform, biotech, Orgenesis Mobile Processing Units and Labs, OMPULs, regenerative medicine, immuno-oncology, advanced therapies, therapeutic development, biotechnology, CGT, personalized medicine, Octomera, clinical development, biomanufacturing, GMP facilities, healthcare collaboration, Vered Caplan